Shire PLC CEO Flemming Ornskov could perhaps be forgiven for sounding like the cat that finally got the mouse when commenting on the June 3 completion of the company's combination with Baxalta Inc., creating "the global leader in rare diseases with the number one rare diseases platform based on both revenue and pipeline programs."
Gaining Baxalta also gives Shire strength in hematology and immunology and boosts its leading position in angioedema, enzyme replacement therapy,...
Read the full article – start your free trial today!
Join thousands of industry professionals who rely on Scrip for daily insights
- Start your 7-day free trial
- Explore trusted news, analysis, and insights
- Access comprehensive global coverage
- Enjoy instant access – no credit card required
Already a subscriber?